Newborn Screening 5 Parameters

The Newborn Screening 5 Parameters test is an early-life laboratory screening panel designed to identify babies who may be at increased risk of selected congenital, endocrine, metabolic or enzyme-related disorders. Many of these conditions may not produce clear symptoms immediately after birth, although they can potentially affect a baby's growth, brain development, metabolism or general health if they remain undetected. Screening helps identify newborns who should receive further clinical evaluation and confirmatory testing as early as possible.

This test is generally performed using a few drops of blood collected from the baby's heel and applied to a special filter-paper card. This is commonly called a heel-prick test, heel-stick test or dried blood spot screening. The sample is analysed for biochemical markers associated with the conditions included in the selected panel. Newborn screening is a screening service and not a definitive diagnostic test. An out-of-range result does not automatically confirm that the baby has a disorder, while an in-range result cannot exclude every possible disease or every rare form of a screened condition.

What Does the Newborn Screening 5 Parameters Panel Include?

The exact composition of a five-parameter newborn screening panel can vary between laboratories, hospitals and regional screening programmes. A commonly offered five-parameter panel may screen for congenital hypothyroidism, congenital adrenal hyperplasia, glucose-6-phosphate dehydrogenase deficiency, galactosemia and biotinidase deficiency. The associated laboratory markers may include thyroid-stimulating hormone, 17-hydroxyprogesterone, G6PD enzyme activity, total galactose and biotinidase activity. Parents and clinicians should confirm the exact five parameters included in this service with Focus Diagnostics before sample collection.

Congenital Hypothyroidism Screening

Congenital hypothyroidism occurs when a newborn does not produce enough thyroid hormone. Thyroid hormone plays an important role in physical growth and brain development. Affected babies can appear healthy during the first days of life, which is why clinical observation alone may not detect the condition promptly. Screening commonly measures thyroid-stimulating hormone, although the testing method and reporting protocol can vary. An abnormal screening value normally requires timely thyroid function testing and assessment by a paediatrician or paediatric endocrinologist.

Congenital Adrenal Hyperplasia Screening

Congenital adrenal hyperplasia is a group of inherited disorders affecting hormone production by the adrenal glands. Screening frequently measures 17-hydroxyprogesterone as a marker for the most common form associated with 21-hydroxylase deficiency. Severe forms may cause salt loss, dehydration, vomiting, poor feeding or circulatory collapse. Prematurity, low birth weight, stress and illness can increase 17-hydroxyprogesterone concentrations and may result in an out-of-range screening result even when the baby does not have congenital adrenal hyperplasia. Confirmatory hormonal testing and specialist evaluation are therefore essential.

G6PD Deficiency Screening

Glucose-6-phosphate dehydrogenase deficiency is an inherited enzyme condition affecting the ability of red blood cells to manage oxidative stress. Some affected newborns may develop significant jaundice or haemolysis, especially after exposure to certain medicines, foods, chemicals or infections. Screening can help families and doctors take appropriate precautions. Recent blood transfusion, the baby's clinical condition and the proportion of young red blood cells may influence enzyme testing. A paediatrician may recommend repeat or confirmatory testing when the clinical history and screening result do not agree.

Galactosemia Screening

Galactosemia refers to inherited conditions in which the body has difficulty processing galactose, a sugar derived from lactose. Classical galactosemia can become serious after milk feeding begins and may be associated with poor feeding, vomiting, jaundice, liver dysfunction, infection or failure to thrive. Screening may measure total galactose or related enzyme activity, depending on the laboratory method. An abnormal screen requires urgent medical assessment and specialised confirmatory testing. Parents should not independently change or stop a newborn's feeding unless instructed by the treating paediatrician.

Biotinidase Deficiency Screening

Biotinidase deficiency is an inherited condition that prevents the body from recycling the vitamin biotin efficiently. Without appropriate treatment, some affected children may develop seizures, skin problems, hair loss, hearing or vision difficulties, breathing problems or developmental concerns. Babies may initially appear well. Screening measures biotinidase enzyme activity, but abnormal results must be confirmed using the laboratory and clinical pathway recommended by the baby's doctor. Early recognition is valuable because effective management is available for confirmed cases.

Why Is Newborn Screening Important?

Newborn screening is intended to detect risk before obvious symptoms develop. Certain disorders included in screening programmes can cause irreversible complications if recognition and treatment are delayed. Timely screening gives the clinical team an opportunity to arrange confirmatory investigations, specialist referral and treatment when required. It also provides parents with information that may help them understand the baby's follow-up needs.

The panel does not examine the newborn for every genetic, metabolic, hormonal or developmental condition. It also does not replace the baby's physical examination, hearing screening, pulse-oximetry screening for critical congenital heart disease, routine paediatric visits, vaccination or any investigation ordered because of symptoms or family history.

Who May Need This Test?

Newborn screening is generally considered for every baby, including babies who look healthy and have no known family history of inherited disease. A clinician may pay particular attention to screening and follow-up when the baby was born prematurely, has a low birth weight, required neonatal intensive care, received a blood transfusion, has been receiving parenteral nutrition or medicines, became unwell after delivery, or has a sibling or relative with an inherited metabolic or endocrine disorder.

A negative family history does not eliminate risk because some screened disorders follow autosomal-recessive inheritance. In such conditions, both parents may be healthy carriers and may be unaware of their carrier status. The baby's paediatrician should determine whether this five-parameter panel or a broader newborn screening panel is appropriate.

Sample Required and Collection Process

The usual specimen is a dried blood spot collected by a trained healthcare professional. The baby's heel is cleaned, a small sterile lancet is used to obtain blood, and drops are allowed to soak through designated circles on a specialised collection card. Correct collection is important. Insufficient blood, layering multiple drops, contamination, incomplete saturation, excessive squeezing of the heel, moisture or inadequate drying can make a specimen unsuitable and may require recollection.

The card must be labelled accurately with information such as the baby's date and time of birth, date and time of collection, gestational age, birth weight, feeding details, transfusion history and relevant treatment. These details can affect result interpretation. The blood spots are dried and transported according to laboratory requirements.

When Should the Sample Be Collected?

Newborn dried blood spot screening is commonly performed after the baby is approximately 24 to 48 hours old, although local protocols may recommend a somewhat different window. Collection before 24 hours of age can affect certain markers and may lead to a recommendation for repeat screening. Screening should not be unnecessarily delayed because some conditions require prompt follow-up.

Premature, low-birth-weight, critically ill or transfused babies may need a modified schedule or repeat samples. If screening was missed before discharge, parents should contact the baby's doctor or laboratory promptly. The appropriate timing must be decided according to the baby's health, age, feeding status and local newborn screening protocol.

Preparation for the Test

Fasting is generally not required for a newborn screening heel-prick test. The baby may usually be fed normally unless a doctor provides different instructions. Parents should tell the collection team about prematurity, neonatal illness, medications, steroid treatment, oxygen support, parenteral nutrition, dialysis, blood transfusion and the time at which milk feeding began. They should also share any known family history of neonatal death, severe newborn jaundice, endocrine disease, metabolic disease or unexplained developmental disability.

Understanding the Results

Results are normally classified according to the laboratory's validated cut-offs and may be reported as in range, screen negative, out of range, screen positive, borderline, inconclusive or sample unsuitable. A screen-negative result means the measured markers did not cross the laboratory's action limits in that specimen. It does not guarantee that the baby is unaffected, because screening tests are not perfectly sensitive and only assess the conditions and markers included in the panel.

An out-of-range or screen-positive result means the baby requires prompt follow-up. It is not a confirmed diagnosis. Biological variation, early sample collection, prematurity, illness, stress, transfusion, medicines, nutrition and technical sample factors can influence results. Follow-up may involve a repeat dried blood spot, venous blood tests, urine testing, enzyme assays, hormone measurements, molecular testing or evaluation by a paediatric specialist.

What Happens After an Abnormal Result?

Parents should follow the laboratory's and paediatrician's instructions without delay. The required action depends on the marker, the degree of abnormality, the baby's age and whether symptoms are present. Some results require urgent same-day clinical assessment, while others may require a carefully timed repeat specimen. Treatment decisions should be made by qualified clinicians after appropriate evaluation. Parents should not start supplements, hormone medicines or a specialised diet solely on the basis of online information or an unconfirmed screening result.

Factors That May Affect the Screening Result

• Collection before the recommended post-birth interval
• Prematurity, low birth weight or neonatal intensive-care admission
• Acute illness, stress, dehydration or liver dysfunction
• Blood or exchange transfusion before collection
• Parenteral nutrition, dialysis or selected medications
• Insufficient, contaminated, wet or improperly dried blood spots
• Delayed transport or unsuitable storage conditions
• Differences in feeding status and timing
• Laboratory-specific methods, reference limits and recall protocols

Important Safety Information

Newborn screening is not an emergency assessment. If a baby develops poor feeding, repeated vomiting, unusual sleepiness, severe or worsening jaundice, breathing difficulty, seizures, fever, low temperature, dehydration, reduced responsiveness or any other serious symptom, parents should seek urgent medical care immediately and should not wait for the screening report.

Test Limitations

This five-parameter panel only evaluates the conditions and biomarkers specified by the performing laboratory. It cannot diagnose all causes of jaundice, vomiting, seizures, hormone abnormalities or developmental problems. Rare disease variants may not produce a clearly abnormal marker at the time of collection. False-positive and false-negative results are possible. Confirmatory testing, clinical examination and ongoing paediatric care remain essential.

Booking the Newborn Screening 5 Parameters Test

The Newborn Screening 5 Parameters test can be booked with Focus Diagnostics for ₹2600. Before booking, confirm the exact five disorders or markers included, the recommended collection time, sample-collection availability, expected reporting schedule and the process used for urgent result communication. This information is educational and does not replace advice from the baby's paediatrician.